Quality Director Responsible Person
BridgeBio
Quality Director Responsible Person
BridgeBio
Develops therapies for genetic diseases
Mavericks Wanted
When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible.
Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.
What You’ll Do
The Sr Director, Head of Quality & Responsible Person, International, leads quality for infigratinib, and will be the designated Responsible Person on the entity's wholesale distribution authorisation. The role reports to the Head of Quality, QED, with a dotted line to local managing director, and is based in the Netherlands. If the entity becomes the marketing authorisation holder for infigratinib, the role also covers the related MAH quality duties. The role holds an unrestricted right of escalation to the entity's full board and is independent of commercial operations and of manufacturing/supply with EU-GDP guidelines, relevant EU directives (including the Falsified Medicines Directive), Dutch Medicines Act, and public service requirements. This role acts as a QA liaison of BridgeBio's contract service providers (CSPs), providing oversight of lot release activities. This role includes reviewing and approving batch records, certificates of analysis, and compliance documents, providing quality review of deviations, change controls, and CAPAs related to assigned CSPs, collaborating closely with CSPs and internal teams such as quality control, manufacturing, regulatory affairs, and supply chain. The role builds and leads a small quality team (deputy RP, QA compliance/QMS, QA operations/GDP), owns the quality management system across the Skeletal Dysplasia assets, and leads WDA licensing, inspection readiness and potentially subsequent MIA readiness, if needed in the future.
Responsibilities
Major Responsibilities / Accountabilities
Other QA/Responsible Person related responsibilities
Where You’ll Work
Who you are
Rewarding Those Who Make the Mission Possible
We have high expectations for our team members. We make sure those working hard for patients are rewarded and cared for in return.
As a global company, our comprehensive benefits may vary based on location. We have high expectations for our team members. We make sure those working hard for patients are rewarded and cared for in return.
For BridgeBio Full-Time U.S Based Roles:
Financial & Rewards
Health & Well-Being
Skill Development & Career Paths:
By applying, you acknowledge that BridgeBio will process your personal information as described in ourGlobal Candidate Privacy Notice.
BridgeBio Pharma develops medicines for genetic diseases using a decentralized subsidiary model, where each subsidiary focuses on a specific disease while sharing central resources. It advances multiple drug programs at once by leveraging genome sequencing, molecular biology, and patient data to translate research into therapies that target underlying genetic causes. The company differentiates itself through its independent subsidiary structure with centralized support, combined with data-driven decision making and a culture of transparent, evidence-based testing. Its goal is to bring effective, disease-modifying therapies to patients faster by advancing a diverse pipeline from discovery to commercialization through partnerships and eventual approval.
Explore more opportunities at BridgeBio